Astena Holdings Co.,Ltd. AI Stock Analysis
Want to see JP:8095 full AI Analyst Report?
Astena Holdings Co.,Ltd. (8095) AI Stock Analysis
Astena Holdings Co.,Ltd.
(TSE/TYO:8095)
The score is primarily held back by uneven financial quality—especially volatile earnings and inconsistent free cash flow—despite improving margins and a return to profitability. Offsetting this, the stock shows supportive technical strength (trading above major moving averages with positive momentum) and an attractive valuation profile (low P/E and solid dividend yield).
Astena Holdings Co.,Ltd. (8095) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 22.48B
- Dividend Yield
- 3.28%
- Average Volume (3M)
- 164.37K
- Price to Earnings (P/E)
- 8.7
- Beta (1Y)
- 0.62
- Revenue Growth
- 13.23%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 1,543
- Sector
- Industrials
- Sector Strength
- 63
- Industry
- Medical - Pharmaceuticals
Astena Holdings Co.,Ltd. Business Overview & Revenue Model
Company Description
Astena Holdings Co., Ltd., a Japanese company founded in 1914 and based in Chuo, is engaged in the development and distribution of a wide array of healthcare and chemical products. Its Fine Chemical division specializes in manufacturing and selling a...
How the Company Makes Money
Astena Holdings makes money primarily through its consolidated subsidiaries’ business activities, with revenue largely generated from the sale and distribution of products handled by the group. Key revenue streams typically include (1) wholesale/dist...
Astena Holdings Co.,Ltd. Financial Statement Overview
Summary
Income statement trends are improving (better gross margin and a return to profit in 2025), but earnings volatility (notably the 2024 loss) and a weaker cash-flow profile weigh heavily. Balance sheet leverage is moderate, though higher debt in 2025 reduces flexibility, and free cash flow has been inconsistent with multiple negative years.
Income Statement
63PositiveBalance Sheet
56NeutralCash Flow
42Neutral| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.74B | 62.74B | 57.99B | 51.98B | 49.64B | 72.32B |
| Gross Profit | 21.87B | 21.87B | 19.37B | 16.32B | 15.44B | 16.60B |
| EBITDA | 5.55B | 5.51B | 849.75M | 4.17B | 3.60B | 4.97B |
| Net Income | 2.19B | 2.19B | -2.53B | 1.16B | 579.60M | 1.74B |
Balance Sheet | ||||||
| Total Assets | 75.44B | 75.44B | 64.60B | 67.25B | 63.55B | 63.55B |
| Cash, Cash Equivalents and Short-Term Investments | 10.19B | 10.19B | 6.10B | 6.88B | 6.93B | 10.93B |
| Total Debt | 22.65B | 22.65B | 14.99B | 16.99B | 15.05B | 15.16B |
| Total Liabilities | 48.04B | 48.04B | 39.29B | 38.65B | 36.48B | 36.55B |
| Stockholders Equity | 27.08B | 27.08B | 25.17B | 28.42B | 26.99B | 27.00B |
Cash Flow | ||||||
| Free Cash Flow | 500.00M | 500.00M | 1.65B | -2.52B | -3.77B | -2.14B |
| Operating Cash Flow | 3.39B | 3.39B | 4.85B | 1.64B | -742.42M | 1.35B |
| Investing Cash Flow | -5.55B | -5.55B | -2.94B | -2.83B | -2.22B | -4.38B |
| Financing Cash Flow | 6.19B | 6.19B | -2.65B | 1.08B | -1.09B | 6.35B |
Astena Holdings Co.,Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:8095, the sentiment is Positive. The current price of 548.00 is above the 20-day moving average (MA) of 535.25, above the 50-day MA of 533.32, and above the 200-day MA of 500.47, indicating a bullish trend. The MACD of 4.47 indicates Negative momentum. The RSI at 55.81 is Neutral, neither overbought nor oversold. The STOCH value of 38.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:8095.
Astena Holdings Co.,Ltd. Peers Comparison
Overall Rating
- JP:809565Neutral
JP:435060Neutral
JP:341752Neutral
JP:279643Neutral
JP:190A38Underperform
JP:489037Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| JP:8095 | 65Neutral | JPY 22.07B | 8.71 | ― | 3.28% | 13.23% | ― |
| Sector * | 63Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% |
| JP:4350 | 60Neutral | JPY 15.99B | 17.47 | ― | 2.31% | 6.89% | -55.21% |
| JP:3417 | 52Neutral | JPY 13.47B | 18.54 | ― | 3.06% | 2.87% | -73.55% |
| JP:2796 | 43Neutral | JPY 5.94B | 59.72 | ― | 2.77% | 7.64% | ― |
| JP:190A | 38Underperform | JPY 3.46B | -2.23 | ― | ― | ― | 24.21% |
| JP:4890 | 37Underperform | JPY 6.13B | -8.36 | ― | ― | -39.46% | -317.84% |
* Industrials Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:8095 | Astena Holdings Co.,Ltd. | 548.00 | 84.78 | 18.30% | |
| JP:2796 | Pharmarise Holdings Corp. | 506.00 | -16.92 | -3.24% | |
| JP:3417 | Ohki Health Care Holdings, Inc. | 980.00 | -400.65 | -29.02% | |
| JP:4350 | Medical System Network Co., Ltd. | 519.00 | 28.22 | 5.75% | |
| JP:4890 | Tsubota Laboratory Incorporated | 233.00 | -100.00 | -30.03% | |
| JP:190A | Chordia Therapeutics Inc. | 45.00 | -62.00 | -57.94% |
Astena Holdings Co.,Ltd. Corporate Events
Astena Holdings Tightens Shareholder Benefit Rules to Reward Long-Term Investors
Astena Holdings Co., Ltd. will revise how it determines categories under its shareholder benefit program, shifting from a single annual reference date to a system that evaluates shareholdings on both May 31 and November 30. The change is intended to...
Astena Holdings Expands PWB Equipment Production With New China Subsidiary
Astena Holdings’ subsidiary Tokyo Kakoki plans to establish Tokyo Kakoki (Zhejiang) Co., Ltd. in Jiaxing, Zhejiang, as a wholly owned second-tier subsidiary to design, manufacture, and sell PWB and flat panel surface treatment equipment. With capital...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 07, 2026